<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04129034</url>
  </required_header>
  <id_info>
    <org_study_id>LBP-002</org_study_id>
    <nct_id>NCT04129034</nct_id>
  </id_info>
  <brief_title>Safety and Initial Feasibility of Using the Neurolyser XR Device for the Treatment of Axial Chronic Low Back Pain</brief_title>
  <official_title>Safety and Initial Feasibility of Using the Neurolyser XR Device for the Treatment of Axial Chronic Low Back Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FUSMobile Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FUSMobile Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single arm pilot study to evaluate the safety and initial feasibility of the Neurolyser XR, a
      high intensity focused ultrasound device, for non-invasive treatment of axial chronic low
      back pain
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: Prospective, single arm

      Timeline: six month enrollment period and 12 months follow-up period.

      Sites: The study will be conducted at five sites in Canada: McGill University, Toronto
      Western, Silver Medical Group, Precision Sport &amp; Spine, Kinetix Integrated Orthopaedic &amp;
      Regenerative Medicine

      Study population: Thirty adult patients diagnosed with facet related low back pain.

      Primary study objective: Safety and efficacy of the Neurolyser XR for the treatment of
      chronic low back pain secondary to zygapophyseal joint syndrome.

      Safety is measured by the incidence and severity of treatment related adverse events.

      Efficacy is measured by the changes in pain severity at the treatment area, using a numerical
      rating scale (NRS), of 0 to 10 between baseline and 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 24, 2019</start_date>
  <completion_date type="Anticipated">September 24, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 24, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm, non-randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>NRS</measure>
    <time_frame>Time Frame: Base line, 2 days 1, 2 &amp; 4 weeks, 3, 6 &amp; 12 months after procedure</time_frame>
    <description>Change in average pain score as measured by a numeric rating scale from 0 (no pain) to 10, worst possible pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedure and Device Safety at six months as measured by measured by the incidence and severity of treatment related adverse events</measure>
    <time_frame>Time Frame: 6 months after procedure</time_frame>
    <description>Safety will be measured by the incidence and severity of treatment related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lesion Size</measure>
    <time_frame>2 days post procedure</time_frame>
    <description>Lesion size and location as shown in MRI Image, 2 days post treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index (ODI)</measure>
    <time_frame>Time Frame: Base line, 1, &amp; 4 weeks, 3, 6 &amp; 12 months after procedure</time_frame>
    <description>Low Back Pain Questionnaire (Range: 0% to 100%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Form 12 (SF-12)</measure>
    <time_frame>Time Frame: Base line, 1, &amp; 4 weeks, 3, 6 &amp; 12 months after procedure</time_frame>
    <description>A multipurpose short form survey with 12 questions (Range: 0 to 100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC)</measure>
    <time_frame>Time Frame: Base line, 1, &amp; 4 weeks, 3, 6 &amp; 12 months after procedure</time_frame>
    <description>Patient Global Impression of Change (Range: 1 to 7)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure and Device Safety as measured by measured by the incidence and severity of treatment related adverse events</measure>
    <time_frame>Time Frame: Base line, Procedure day, 2 days 1, 2 &amp; 4 weeks, 3, 6 &amp; 12 months after procedure</time_frame>
    <description>Safety will be measured by the incidence and severity of treatment related adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Facet Syndrome of Lumbar Spine</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thermal ablation of the medial nerve branch using High Intensity Focused Ultrasound</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neurolyser XR</intervention_name>
    <description>Non-Invasive Thermal Ablation of the Medial Branch Nerves</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult male and females &gt;55 years of age legally able and willing to participate in the
             study and come for follow-up visits

          2. Able and willing to fill the research questionnaires and to communicate with
             investigator and research team

          3. Patient with bilateral or unilateral low back pain of &gt; 6 months duration

          4. Patients whose back pain is alleviated by recumbency or comfortable sitting position

          5. Patients presenting with a) a positive (&gt;70% pain relief) to a previous, single or
             double, L1 to L5 lumbar medial branch block (within the last 12 months) and / or b)
             with a positive (&gt;70% pain relief lasting more than 6 months) to a previous lumbar
             facet thermal radiofrequency denervation.

          6. Average pain score of 6 or higher in the last month, (on 0-10 scale).

        Exclusion Criteria:

          1. Pregnant or breastfeeding patient

          2. Patients younger than 55 or older than 85 years

          3. Patients presenting with neurological deficits (including lumbosacral radiculopathy
             but not solitary radicular pain).

          4. Patients with history of lumbosacral spine surgery excluding previous lumbar
             radiofrequency neurotomy

          5. Patients who have had lumbar radiofrequency neurotomy in the past 6 months

          6. Patients with the presence of metal hardware or other foreign objects at the
             lumbosacral spine

          7. Patients with history of lumbar spine pathology that may increase procedural risk and
             / or influence symptoms and / or generate unrelated adverse event, (per the discretion
             of the study PI)

          8. Patients unable to understand and complete the research questionnaires in the official
             language used within the particular sites' location.

          9. Patients presenting with any severe medical condition preventing the patient from
             safely and effectively being treated in the study or reporting study outcome per PI
             decision.

         10. Patient with extensive scarring of the skin and tissue overlying the treatment area.

         11. Patients enrolled in or planned to be enrolled in another clinical trial during the
             duration of this research project

         12. Any patients with an uncontrolled coagulopathy

         13. Patients with known osteoporosis with absolute risk of spinal fracture of &gt;10% over 10
             years will be excluded

         14. Any patients with a history of malignant disease in the past five years

         15. Patients with rheumatologic diseases causing spine pain that are currently receiving
             active treatment including steroids, disease modifying drugs, biological agents or
             immunosuppressants.

         16. Patients known for concomitant psychiatric disorders, excluding mood disorders.

         17. Patients presenting with concomitant mood disorders (deemed severe by the research
             physician).

         18. Patients with a first-degree family member already enrolled in this study.

         19. Patient who is scheduled for any interventional/surgical procedure within 3 months
             from screening date

         20. Patients diagnosed with co-morbid multifocal chronic pain (e.g., fibromyalgia)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michael Gofeld, MD</last_name>
    <phone>416.512.6407</phone>
    <email>mikegofeld@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kinetix Medicine</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>BC V6K 2E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jillian Fyvie</last_name>
      <phone>604.416.0630</phone>
      <email>jillian@kinetixmedicine.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Precision Sport &amp; Spine</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6L 1H5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magen Clark</last_name>
      <phone>905-857-5755</phone>
      <email>admin@precisionss.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Silver Medical Group</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3H 5S4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annelise Marsig</last_name>
      <phone>416.512.6407</phone>
      <email>annelise.marsig@silverpaincare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toronto Western</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamal Kara</last_name>
      <phone>(416)-603-5800</phone>
      <phone_ext>6237</phone_ext>
      <email>jamal.kara@uhn.ca</email>
    </contact>
    <contact_backup>
      <last_name>Deepti Kallam</last_name>
      <phone>(416)-603-5800</phone>
      <phone_ext>2016</phone_ext>
      <email>deepti.kallam@uhnresearch.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Alan Edwards Pain Management Unit - Montreal General Hospital</name>
      <address>
        <city>Montr√©al</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvie Toupin</last_name>
      <email>sylvie.toupin@muhc.mcgill.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic low back pain</keyword>
  <keyword>zygapophyseal joint syndrome</keyword>
  <keyword>Facet syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

